BW-20507

· Shanghai Argo Biopharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BW-20507, covering 2026-01-15 to 2026-01-15. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B [Phase 2]